PD-L1 Binding Adnectins for PET Imaging Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and imaging techniques lack effective methods for specifically targeting and visualizing PD-L1 expressing cells or tumors, which are crucial for cancer treatment and monitoring, as existing methods are non-specific and inefficient.
Innovation Solution
Development of novel anti-human PD-L1 Adnectins, which are polypeptides based on the fibronectin type III tenth domain, specifically designed to bind to PD-L1 with high affinity, used as diagnostic and imaging agents in positron emission tomography (PET) to differentiate PD-L1 expressing cells or tissues from non-expressing ones.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging techniques are used, then imaging capability is provided, but specificity for PD-L1 expressing cells is insufficient
Solution Approach 1:
The patent modifies the fibronectin type III domain structure by altering specific amino acid residues (such as K78Q mutation) to change the binding parameters of the protein, enabling it to specifically recognize and bind to PD-L1 with high affinity while maintaining structural stability
Solution Approach 2:
The invention introduces specific local modifications to the 10Fn3 domain structure, particularly in the loop regions (such as the DE loop), to create localized binding interfaces that specifically interact with PD-L1 epitopes, thereby achieving high specificity without affecting overall protein function
2Measurement precision
If existing diagnostic methods are used, then general detection is possible, but differentiation of PD-L1 expressing cells from non-expressing cells is not achieved
Solution Approach 1:
The patent extracts and isolates the specific binding capability from the complex fibronectin structure by creating a simplified 10Fn3 domain variant that retains only the essential PD-L1 binding function, eliminating unnecessary complexity while maintaining detection accuracy
Solution Approach 2:
The invention creates a simplified copy of the natural fibronectin binding domain (10Fn3) with modified sequences that replicate and enhance the specific binding function to PD-L1, providing a cleaner, more specific detection tool without the complexity of full-length fibronectin
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-PD-L1 Adnectins enable precise visualization and quantification of PD-L1 expression in tissues and tumors using PET, allowing for effective cancer diagnosis, treatment monitoring, and therapeutic targeting of PD-L1 positive cells.
Implementation Method 1
the polypeptide specifically binds to PD-L1
Implementation Method 2
PET, or Positron Emission Tomography, is a non-invasive, nuclear medicine technique that produces a three-dimensional image of various molecular processes within the body, or the location of proteins associated with disease pathology. The methodology detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer)
Data Source
AI summary
Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.